AbbVie (ABBV) Expected to Announce Quarterly Earnings on Wednesday

AbbVie (NYSE:ABBV) is expected to post its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect AbbVie to post earnings of $3.37 per share and revenue of $16.3913 billion for the quarter. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 9:00 AM ET.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the business posted $3.00 earnings per share. On average, analysts expect AbbVie to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

AbbVie Trading Up 1.4%

NYSE:ABBV opened at $223.92 on Wednesday. The business’s 50-day moving average is $225.14 and its 200 day moving average is $218.00. AbbVie has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a market capitalization of $395.75 billion, a P/E ratio of 169.64, a P/E/G ratio of 0.91 and a beta of 0.36.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is presently 524.24%.

Institutional Investors Weigh In On AbbVie

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quarry LP purchased a new stake in AbbVie during the third quarter worth approximately $41,000. Rakuten Securities Inc. lifted its holdings in AbbVie by 26.5% during the 2nd quarter. Rakuten Securities Inc. now owns 368 shares of the company’s stock worth $68,000 after buying an additional 77 shares during the last quarter. Binnacle Investments Inc lifted its position in shares of AbbVie by 33.2% in the 2nd quarter. Binnacle Investments Inc now owns 493 shares of the company’s stock worth $92,000 after buying an additional 123 shares during the last quarter. Triumph Capital Management bought a new stake in shares of AbbVie in the 3rd quarter worth approximately $193,000. Finally, Wealth Watch Advisors INC acquired a new stake in shares of AbbVie in the 3rd quarter worth about $210,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several analyst reports. Morgan Stanley increased their price target on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Finally, Scotiabank began coverage on shares of AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $247.84.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck billion‑dollar licensing deals with Novartis for oncology and Alzheimer’s programs, which expand near‑ and long‑term revenue optionality and signal external validation of AbbVie’s R&D. AbbVie and Novartis Announce Billion Dollar Licensing Deals for Oncology and Alzheimer’s Treatments
• Positive Sentiment: Berenberg raised its price target (to $275) and remains bullish on Skyrizi and Rinvoq momentum, a supportive analyst view that can boost investor sentiment. Berenberg Grows More Confident in AbbVie on Skyrizi and Rinvoq Momentum
• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector delivering risankizumab, which could improve dosing convenience and broaden uptake for indications served by Skyrizi. This is a pipeline/utility win. AbbVie Advances Risankizumab Delivery With On‑Body Injector Study Completion
• Positive Sentiment: Small institutional buying reported (Belpointe Asset Management increased its stake), a modest signal of shareholder confidence. Belpointe Asset Management LLC Increases Stake in AbbVie Inc. $ABBV
• Neutral Sentiment: Options and retail interest are elevated (coverage from Zacks on options flow and trending status); this can increase volatility but isn’t a fundamental catalyst by itself. Is the Options Market Predicting a Spike in AbbVie Stock?
• Neutral Sentiment: Corporate social impact news (AbbVie Foundation accelerator) and dividend‑king listings support the long‑term income story but are not immediate earnings drivers. The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator
• Negative Sentiment: The U.S. Medicare Drug Price Negotiation Program named several AbbVie drugs for its next negotiation cycle, including Part B products — a direct pricing risk that could pressure future revenues if negotiated prices are reduced. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: A competitor (Corcept) reported robust Phase III efficacy for an ovarian cancer drug, which could threaten market share in oncology areas where AbbVie competes. Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
• Negative Sentiment: Citigroup trimmed its price target to $230 and assigned a neutral rating, a modest analyst headwind that may cap upside near‑term. Citigroup Lowers Price Target on AbbVie

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.